79 reports of this reaction
3.3% of all DANTROLENE SODIUM reports
#1 most reported adverse reaction
NEUROLEPTIC MALIGNANT SYNDROME is the #1 most commonly reported adverse reaction for DANTROLENE SODIUM, manufactured by Endo USA, Inc.. There are 79 FDA adverse event reports linking DANTROLENE SODIUM to NEUROLEPTIC MALIGNANT SYNDROME. This represents approximately 3.3% of all 2,376 adverse event reports for this drug.
Patients taking DANTROLENE SODIUM who experience neuroleptic malignant syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROLEPTIC MALIGNANT SYNDROME is moderately reported among DANTROLENE SODIUM users, representing a notable but not dominant share of adverse events.
In addition to neuroleptic malignant syndrome, the following adverse reactions have been reported for DANTROLENE SODIUM:
The following drugs have also been linked to neuroleptic malignant syndrome in FDA adverse event reports:
NEUROLEPTIC MALIGNANT SYNDROME has been reported as an adverse event in 79 FDA reports for DANTROLENE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROLEPTIC MALIGNANT SYNDROME accounts for approximately 3.3% of all adverse event reports for DANTROLENE SODIUM, making it one of the most commonly reported side effect.
If you experience neuroleptic malignant syndrome while taking DANTROLENE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.